• FY24 revenue of $26.5m, up 34% vs pcp; up 27% on a constant currency basis
• FY24 Underlying EBITDA was a profit of $0.5m; $0.2m in pcp
• ARR of $30.0m, up 20% vs pcp; up 24% on a constant currency basis

IMEXHS Ltd reported its FY24 results and announced a capital raising. Key highlights include:- FY24 revenue of $26.5m, up 34% year-on-year and 27% on a constant currency basis- FY24 Underlying EBITDA was a profit of $0.5m, up from $0.2m in the prior year- Annualised Recurring Revenue (ARR) of $30.0m, up 20% year-on-year and 24% on a constant currency basis- Cash of $2.1m at 31 Dec 2024, down from $2.4m at 31 Dec 2023- Launched new Aquila+ software solution, designed to improve radiology workflow productivity, with initial installations complete at 8 sites- Advanced negotiations for a new material radiology contract in Colombia expected to generate $600,000 monthly recurring revenue- Equity raising of up to $3.5m comprising a $2.5m placement (including $1m from directors) and a $1m share purchase plan for existing shareholdersThe company is focused on generating positive earnings and cash flow, with geographic attention remaining within Latin America. Sales pipelines for both IMEXHS Cloud and Enterprise radiology solutions remain robust. The new Aquila+ software development is on track for progressive release from Q1 2025, with early benefits including improved software resilience, service response times and radiologist productivity.

The company expects strong revenue growth and to be EBITDA and cashflow positive for 2025, with more of the growth expected to occur in H2 2025. Specific guidance will be provided at the half year.

Key drivers for revenue and earnings growth include the company's Annualised Recurring Revenue together with its current pipeline, overall improvement in Radiology Services margin, and the progressive launch of the new Aquila+ software from the end of Q1 2025.